Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing ...
By Bleichmar Fonti & Auld - Apr 05, 2025, 07:12 AM ET
Last Updated - Apr 05, 2025, 07:12 AM EDT
NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws.
If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Why is Aldeyra Therapeutics being Investigated?
Aldeyra Therapeutics is a biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases. The company’s lead drug candidate, reproxalap, is being developed for the treatment of dry eye disease.
During the relevant period, Aldeyra Therapeutics announced the success of its Phase III dry eye chamber clinical trial for reproxalap. The company stated that the trial’s results were “uniquely supportive” of reproxalap’s effect on reducing ocular discomfort and that reproxalap was the first investigational drug with “pivotal data” to support reducing redness. What’s more, the company stated that the trial “satisfies FDA requirements” for New Drug Application resubmission.
In truth, Aldeyra Therapeutics’ Phase III trial failed to demonstrate reproxalap’s efficacy in treating ocular symptoms associated with dry eyes. The Phase III trial data suffered from potential methodological issues, including a difference in baseline scores across treatment arms, that did not satisfy the FDA requirements for NDA resubmission.
The Stock Declines as the Truth is Revealed
On April 3, 2025, Aldeyra Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for reproxalap. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes.” The FDA identified concerns with the trial data submitted with the NDA, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms. This news caused the price of Aldeyra Therapeutics stock to fall nearly 75% over the course of the trading day, from a closing price of $5.33 per share on April 2, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
What Can You Do?
If you invested in Aldeyra Therapeutics you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc
Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc
Attorney advertising. Past results do not guarantee future outcomes.
Sponsored
Read More from Press Releases
Popular News
Latest News
